SCHEMBL2282295

SCHEMBL2282295

CC(=O)N1CCC(n2c(=O)n(C)c3cnc4ccc(-c5ccc(N)nc5)nc4c32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 20/20 1.00
▸ MTOR P42345 20/20 1.00
▸ PIK3CD O00329 1/20 0.67
▸ PIK3CG P48736 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2277820 0.92 PIK3CA (0.85) PIK3CAMTOR
SCHEMBL2277731 0.90 PIK3CA (1.00) PIK3CAMTORPIK3CDPIK3CG
SCHEMBL12376305 0.89 PIK3CA (0.85) PIK3CAMTORPIK3CDPIK3CG
SCHEMBL2283791 0.89 MTOR (1.00) PIK3CAMTOR
SCHEMBL2280276 0.88 PIK3CA (1.00) PIK3CAMTOR
SCHEMBL2284485 0.88 PIK3CA (1.00) PIK3CAMTOR
SCHEMBL2280472 0.88 MTOR (1.00) PIK3CAMTOR
SCHEMBL2282500 0.86 MTOR (1.00) PIK3CAMTOR
SCHEMBL2282281 0.86 PIK3CA (1.00) PIK3CAMTORPIK3CDPIK3CG
SCHEMBL2282247 0.86 MTOR (0.83) PIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356120-B1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER (US) 2016-10-12 — — EP claimed
EP-2356120-B1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER (US) 2016-10-12 — — EP disclosed
EP-2356120-B1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER (US) 2016-10-12 — — EP disclosed
US-8791131-B2 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions PFIZER INC. (US) 2014-07-29 — — US disclosed
US-8791131-B2 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions PFIZER INC. (US) 2014-07-29 — — US disclosed
US-8791131-B2 Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions PFIZER INC. (US) 2014-07-29 — — US disclosed
EP-2356120-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS Pfizer Inc. (US) 2011-08-17 — — EP disclosed
US-20110190326-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. 2011-08-04 — — US disclosed
US-20110190326-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. 2011-08-04 — — US disclosed
US-20110190326-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. 2011-08-04 — — US disclosed
WO-2010038165-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. (US) 2010-04-08 — — WO disclosed
WO-2010038165-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC. (US) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190326-A1 IMIDAZO[1,5]NAPHTHYRIDINE COMPOUNDS, THEIR PHARMACEUTICAL USE AND COMPOSITIONS PIK3CA, PIK3CD, PIK3R5 PIK3CA 1/4885MTOR 4/4885PIK3CD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback